Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
7.10.2019 15:30:00 EEST | Business Wire | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company’s global clinical development and medical affairs organizations. He will join the company’s senior leadership team and will report directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. Under a new structure, William Lee, PhD, Gilead’s Executive Vice President, Research will separately report to Mr. O’Day.
Dr. Parsey joins Gilead from Genentech, Inc., a member of the Roche Group, where he currently holds the position of Senior Vice President, Early Clinical Development in the Genentech Research and Early Development (gRED) group. In this role, he leads clinical development, quality, compliance, informatics and clinical operations functions. He brings to Gilead significant clinical expertise across a broad array of therapeutic areas, including inflammation, oncology and infectious diseases.
“I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead,” said Mr. O’Day. “Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”
Prior to his most recent tenure with Genentech, Dr. Parsey served as President and CEO of 3-V Biosciences. He has also held development roles at Sepracor, Regeneron and Merck, Inc. and has served as Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.
“I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired,” said Dr. Parsey. “I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005221/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Marni Kottle, Media
(650) 522-5388
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Skechers Enters Super Shoe Era With Innovative Skechers AERO Elite1.10.2026 15:20:00 EEST | Press release
Skechers is redefining what it means to run fast with the Skechers AERO Elite. The latest addition to the innovative Skechers AERO Series makes its global racing debut today—marking a landmark moment as the performance brand’s first super shoe. Engineered to perform from 5Ks to marathons, the design minimizes weight and maximizes responsiveness, all while delivering Skechers’ signature comfort. The AERO Elite is built to win with the performance runners at any level need to go further, faster, and achieve that next personal record. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001865320/en/ Introducing the Skechers AERO Elite, the brand’s first super shoe designed for racing. “The Skechers AERO Elite is the culmination of years of elite-level running innovation—our most technically advanced running shoe to date and a direct statement of intent as we look ahead to the 2028 Summer Games in Los Angeles,” said Catherine Zou,
Visa Data Shows Stablecoins Gaining Traction in Business Payments1.10.2026 15:00:00 EEST | Press release
Today, Visa (NYSE: V) shared new data showing the growing adoption of stablecoins across business payments and commercial card programs, underscoring how stablecoins are increasingly being used as financial infrastructure. The findings come as businesses, financial institutions and payment providers increasingly explore stablecoins for settlement, treasury management, payouts and cross-border commerce. New Visa data shows: Approximately 17% of stablecoin-linked card volume in FY26 year-to-date occurred across business and commercial card programs. Visa today supports more than 160 stablecoin-linked card programs spanning consumer, business and commercial card activity. Payments volume across these programs has grown nearly 200% year over year. Businesses are increasingly exploring stablecoins for settlement, treasury management, payouts and cross-border commerce. "Businesses aren't looking for new payment technologies for the sake of innovation. They’re looking for trusted, reliable wa
New Research: Organizations with Strong Process Context 5x More Likely to Deliver Successful AI Outcomes1.10.2026 15:00:00 EEST | Press release
Organizations with strong process context are five times more likely to report very successful AI outcomes, according to new research from The Hackett Group® and ARIS, highlighting the critical role business understanding plays in enabling enterprises to deploy agentic AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001144480/en/ The Process Context Study 2026 found that companies experienced with strong process context were 5x more likely to be seeing successful outcomes from AI The Process Context Study 2026 examines how prepared Global 2000 companies are to deploy agents into core business processes and how process context is key to agents operating reliably and securely at enterprise-level, driving measurable new business value. The findings expose a significant gap between enterprise AI ambition and current operational readiness: 86% of respondents believe agents cannot be deployed reliably without proces
NetApp Recognizes Winners of 2026 North America Partner Awards1.10.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced at NetApp INSIGHT 2026 the winners of its North America Partner Awards for Fiscal Year 2026 (FY’26). NetApp’s strategic partnerships aid in providing NetApp products and solutions to solve the business challenges of their joint customers. The North America Partner Award winners have been instrumental in helping customers to build an Intelligent Data Infrastructure through the NetApp Platform, that can securely evolve and scale with their needs by driving sales of NetApp’s solutions and services. Each winning partner has demonstrated a thorough understanding of the NetApp portfolio and has proven their ability to leverage NetApp’s innovative solutions and services to give customers the confidence they need to overcome today’s biggest technology challenges. “Now more than ever, we must empower customers with AI-ready data that is secure by default and built for hybrid environments so they can achieve the
Moody’s Analytics and Allvue Launch Credit Risk Model to Identify Early Signs of Borrower Stress in Private Credit1.10.2026 15:00:00 EEST | Press release
Moody’s Corporation (NYSE: MCO), a global leader in risk assessment and credit analytics, and Allvue Systems, LLC, a leading technology and data provider for private capital markets, today announced the launch of the Moody’s Analytics EDF-X Private Credit Model, a new forward-looking credit risk model purpose-built for the private credit market. Built on Moody’s deep credit expertise and Allvue’s private credit performance data, the model identifies early signals of borrower stress, such as covenant waivers and payment-in-kind arrangements, well before they show up as missed payments or defaults. Moody’s projects private credit to approach $4 trillion in assets by 2030, and investors and lenders are increasingly seeking earlier visibility on where risk is building across portfolios. Unlike public credit markets where participants have the benefit of access to published credit ratings, financial disclosures, and transparent pricing, private credit often relies on proprietary credit asse
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom